{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:44:33Z","timestamp":1794707073519,"version":"4.9.1"},"reference-count":0,"publisher":"American Society of Hematology","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Adult T-cell leukemia\/lymphoma (ATL) is associated with a dismal prognosis in aggressive subtypes, with a median overall survival (OS) of less than one year. In Japan, first line chemotherapy followed by allogeneic stem cell transplantation (allo-SCT) is recommended for eligible patients, yet this strategy is scarcely reported elsewhere, especially among ethnic minorities. We prospectively evaluated the feasibility and outcome of allo-SCT in this setting. Between 2016 and 2024, 80 ATL patients were enrolled; 74 (median age 50 years) received frontline chemotherapy (CHO(E)P regimen +\/-Brentuximab Vedotin in CD30 positive cases). Of these, 39 subsequently proceeded to allo-SCT using a Thiotepa-Busulfan-Fludarabine conditioning regimen after at least one line of chemotherapy. Two-year OS from first line therapy was 45 %. Time-dependent analysis demonstrated a significant survival benefit for allo-SCT (hazard ratio, 0.32). Uncontrolled disease was the primary reason for transplant ineligibility. At transplantation, 27 patients were in complete remission (CR,) 5 in partial response (PR) and 7 had stable\/progressive disease. Donor sources included haploidentical (56%), matched sibling (26%), and unrelated donors (18%). Three-year OS and progression-free survival were both 52%, while one-year non-relapse mortality and cumulative relapse incidence were 15% and 35%, respectively. Absence of CR\/PR at allo-SCT was the main risk factor for poor outcomes. Tailored HTLV-1\/ATL molecular and flow-cytometric monitoring of assessable patients in remission, revealed that tumor clones became undetectable after allo-SCT, suggesting a potent graft-versus-ATL effect. Overall, our findings support the benefit of allo-SCT in eligible ATL patients. Clinical Trial Identifier: NCT05237245.<\/jats:p>","DOI":"10.1182\/bloodadvances.2026020323","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:02:27Z","timestamp":1791410547000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic stem cell transplantation in aggressive Adult T cell leukemia\/lymphoma: a prospective multicenter study"],"prefix":"10.1182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-7920","authenticated-orcid":false,"given":"Ambroise","family":"Mar\u00e7ais","sequence":"first","affiliation":[{"name":"H\u00f4pitaux universitaires de Strasbourg, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovick","family":"Lhermitte","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Necker Enfants-Malades, Paris, France, Paris, Alabama, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-2990","authenticated-orcid":false,"given":"Veronique","family":"Avettand Fenoel","sequence":"additional","affiliation":[{"name":"H\u00f4pital Necker"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5331-2364","authenticated-orcid":false,"given":"Amani","family":"Ouedrani","sequence":"additional","affiliation":[{"name":"Assistance Publique -Hopitaux De Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemence","family":"loiseau","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Necker Enfants-Malades, Paris, France, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Cazelles","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Necker Enfants-Malades, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Naveau","sequence":"additional","affiliation":[{"name":"Necker-Enfants Malades University Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Institut Curie, Hematology department, Saint Cloud, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Debus","sequence":"additional","affiliation":[{"name":"CHU Martinique, Fort de France, Martinique"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipe","family":"H\u00e9lias","sequence":"additional","affiliation":[{"name":"CHU de la Guadeloupe, Les Abymes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-2967","authenticated-orcid":false,"given":"Alice-Andr\u00e9e","family":"Mariaggi","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-1239","authenticated-orcid":false,"given":"Viviane","family":"Gournay","sequence":"additional","affiliation":[{"name":"Piti\u00e9-Salp\u00eatri\u00e8re Hospital, APHP, PARIS, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Caillon","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Saint Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Ingen-Housz-Oro","sequence":"additional","affiliation":[{"name":"Department of Dermatology, AP-HP, H\u00f4pital Henri-Mondor, 94220 Cr\u00e9teil, France, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Corvilain","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Gandhi-Laurent","family":"Damaj","sequence":"additional","affiliation":[{"name":"Caen University Hospital, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Hopital Pitie Salpetriere, Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Aubert","sequence":"additional","affiliation":[{"name":"Univ. Grenoble-Alpes, CHU Grenoble Alpes, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-5939","authenticated-orcid":false,"given":"Michael","family":"Loschi","sequence":"additional","affiliation":[{"name":"Nice University Hospital, Cote d'Azur University, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Asnafi","sequence":"additional","affiliation":[{"name":"Laboratory of Onco-Hematology, Assistance Publique-Hopitaux De Paris (AP-HP), Hopital Necker Enfants-Malades, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Suarez","sequence":"additional","affiliation":[{"name":"Necker Hospital, APHP, Universit\u00e9 Paris Cit\u00e9, paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2574-3874","authenticated-orcid":false,"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Necker Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,7]]},"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026020323\/2594131\/bloodadvances.2026020323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2026020323\/2594131\/bloodadvances.2026020323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:02:28Z","timestamp":1791410548000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/doi\/10.1182\/bloodadvances.2026020323\/571419\/Allogeneic-stem-cell-transplantation-in-aggressive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020323","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"bloodadvances.2026020323"}}